Panion & Bf Biotech Inc.

Globoasia, LLC

Panion & Biotech Inc.

Keith Chan

Winston Town

David W K Kwok

Nikolay Mintchev Stoynov

Shou Shan Chiang

The present invention discloses pharmaceutical-grade ferric organic compounds having enhanced dissolution rate. These ferric organic compounds, including but are not limited to ferric citrate, are useful for treating chronic kidney disease.

Method of treating chronic kidney disease

The present invention provides methods of treating soft tissue calcification in a subject, comprising a step of administering to said subject an effective amount of ferric organic compound, such as ferric citrate. The claimed methods may prevent, reverse, delay or stabilize soft tissue calcification in a subject having chronic kidney disease. Affected soft tissue calcification includes soft tissue calcification in the joint, skin, eye, in cardiovascular system such as heart valve, myocardium, coronary arteries and arteriole, or in internal organs such as kidney and lung.

Method for reversing, preventing, delaying or stabilizing soft tissue calcification

The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.

Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same

Method of reversing, preventing, delaying or stabilizing soft tissue calcification

A method of selecting or determining a candidate compound suitable for use as a phosphate binder is disclosed. The candidate compound includes ferric compounds, ferric compound complexes, and their derivatives, salts, analogs, and metabolites. The effectiveness of the candidate compound as a phosphate binder is evaluated by a method, comprising measuring and correlating reduction of phosphate concentration in solution and reduction of phosphate absorption in cells.

Method of selecting phosphate binder and its uses thereof

The present invention discloses a pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.

Growing community of inventors

Rockville, MD, United States of America

Keith Chan